Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
沙参麦冬颗粒治疗慢性咳嗽(咳嗽变异性哮喘)(肺阴亏虚证)有效性和安全性的随机、双盲、安慰剂平行对照、多中心Ⅲ期临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial on the efficacy and safety of Shashen Maidong Granule in the treatment of chronic cough (cough variant asthma) (lung yin deficiency syndrome)
评价沙参麦冬颗粒治疗慢性咳嗽(咳嗽变异性哮喘)(肺阴亏虚证)的有效性和安全性。
[Translation] To evaluate the efficacy and safety of Shashen Maidong Granule in the treatment of chronic cough (cough variant asthma) (lung yin deficiency syndrome).
评价沙参麦冬颗粒治疗感染后咳嗽、咳嗽变异性哮喘(肺阴亏耗证)有效性和安全性的临床试验
[Translation] Clinical trial to evaluate the efficacy and safety of Shashen Maidong granules in the treatment of post-infectious cough and cough variant asthma (lung yin deficiency syndrome)
初步评价沙参麦冬颗粒治疗亚急性、慢性咳嗽(肺阴亏耗证)有效性和安全性
[Translation] Preliminary evaluation of the efficacy and safety of Shashen Maidong granules in the treatment of subacute and chronic cough (lung yin deficiency syndrome)
100 Clinical Results associated with Hubei Liyi Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Hubei Liyi Pharmaceutical Technology Co., Ltd.
100 Deals associated with Hubei Liyi Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Hubei Liyi Pharmaceutical Technology Co., Ltd.